Valrubicin in refractory non-muscle invasive bladder cancer
- 14 November 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 15 (12) , 1379-1387
Abstract
Valrubicin in refractory non-muscle invasive bladder cancer. . ???aop.label???. doi: 10.1586/14737140.2015.1115350Keywords
This publication has 41 references indexed in Scilit:
- A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer GroupJournal of Urology, 2011
- Perioperative Mortality Is Significantly Greater in Septuagenarian and Octogenarian Patients Treated With Radical Cystectomy for Urothelial Carcinoma of the BladderUrology, 2011
- Risk factors for mortality and morbidity related to radical cystectomyBJU International, 2008
- Intravesical Treatments of Bladder Cancer: ReviewPharmaceutical Research, 2008
- Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, 2007
- Bladder CancerJournal of the National Comprehensive Cancer Network, 2006
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and ToxicityJournal of Urology, 2003
- Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experienceUrology, 2002
- Preclinical Rationale and Phase I Clinical Trial of the Adriamycin Analog, AD 321981